2023-09-10 etoricoxib VS diclofanac

MichaelNg

抽象的
目的： 本分析的目的是比較依托考昔和雙氯芬酸治療下頜阻生第三磨牙手術圍手術期後遺症的療效。


材料和方法： 本研究選擇了 97 名需要手術撕脫下頜阻生第三磨牙的患者。所有患者均被隨機分配接受以下治療之一，手術後每天兩次，持續 5 天：安慰劑 (n=33)、雙氯芬酸 (n=32) 或依托考昔 (n=32)。評估的主要結果是術後疼痛，由每位患者記錄並使用視覺模擬量表評分進行評估。選擇的次要結果是與術前相比，術後腫脹和最大張口度的變化。


結果： 與安慰劑相比，依托考昔和雙氯芬酸治療的主要結局有所改善。此外，與其他組相比，接受依托考昔治療的患者術後2 小時（P<0.001）、12 小時（P=0.025）和48 小時（P=0.018）時的術後疼痛中位數顯著減輕。 。此外，線性回歸分析顯示，雙氯芬酸和依托考昔對術後2、6、12、24、48小時和10天的視覺模擬量表有顯著影響。各組之間的腫脹和最大張口值沒有差異。


討論： 本研究證明兩種治療方法均有效。然而，與雙氯芬酸和安慰劑相比，依托考昔治療可顯著降低第三磨牙術後術後疼痛的發生率和嚴重程度。

MichaelNg

Objective: The objective of this analysis was to compare the efficacy of etoricoxib and diclofenac in the management of perioperative sequelae following impacted mandibular third molar surgery.


Materials and methods: Ninety-seven patients who needed surgical avulsion of an impacted mandibular third molar were chosen for the study. All patients were randomly allocated to receive one of the following treatments, twice a day for 5 days after surgery: placebo (n=33), diclofenac (n=32), or etoricoxib (n=32). The primary outcome evaluated was postoperative pain, recorded by each patient and evaluated using the Visual Analogue Scale score. The secondary outcomes chosen were, compared with preoperative ones, changes in postoperative swelling and maximum mouth opening.


Results: Compared with placebo, treatment with etoricoxib and diclofenac demonstrated an enhancement in the primary outcome. Furthermore, when compared with the other groups, patients who had undergone etoricoxib presented a significant median reduction in postoperative pain at 2 hours (P<0.001), 12 hours (P=0.025), and at 48 hours (P=0.018) after surgery. Moreover, the linear regression analysis showed that diclofenac and etoricoxib determined a significant influence on Visual Analogue Scale at 2, 6, 12, 24, 48 hours and at 10 days after surgery. There were no differences in swelling and maximum mouth opening values between groups.


Discussion: This study demonstrated that both treatments were effective. However, treatment with etoricoxib showed a greater reduction in the incidence and severity of postoperative pain following third molar surgery compared with diclofenac and placebo.